From GlobeNewswire: 2024-09-03 20:16:18

Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical and drug development company, has appointed Dr. Hendrik P. N. Scholl as Chief Medical Officer. Dr. Scholl is a global leader in the field of ophthalmology and is known for his expertise in treating retinal diseases. He will play a key role in the development of innovative therapies for retinal degenerative diseases, including Stargardt disease and late-stage dry age-related macular degeneration (AMD). Belite Bio’s candidate drug, Tinlarebant, is currently being evaluated in clinical trials for these conditions. Dr. Scholl’s wealth of experience and expertise will be invaluable in advancing these treatments. For more information, visit www.belitebio.com.



Read more at GlobeNewswire: Belite Bio 宣佈委任醫學博士Hendrik P. N. Scholl 為首席醫療總監